Statutory Instrument laid in Parliament provides first regulatory framework of its kind that will transform the manufacture of innovative medicines at the point of patient care

On "21/10/2024", the "Medicines and Healthcare products Regulatory Agency (MHRA)" issued an update regarding "Statutory Instrument laid in Parliament provides first regulatory framework of its kind that will transform the manufacture of innovative medicines at the point of patient care". This novel UK regulatory framework enables the safe development of innovative, personalised products such as cell or gene therapy. The regulation will facilitate the delivery of care where it is most appropriate for patients, reducing pressures on hospitals and increasing the accessibility of innovative treatments.